Electronic healthcare records (EHR)
An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of OpzeluraTM (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS)
France
Germany
United States
EU PAS number:
EUPAS1000000413
First published:
21/05/2025
StudyPlanned
Safety and effectiveness of LORLAtinib as a FIRST-line treatment in an ALK-positive Advanced Non-Small Cell Lung Cancer Spanish population. (LORLA-FIRST).
Spain
EU PAS number:
EUPAS1000000406
First published:
04/06/2025
StudyPlanned
A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK
France
Spain
United Kingdom
EU PAS number:
EUPAS1000000400
First published:
25/02/2025
StudyPlanned
A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK
Denmark
France
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000399
First published:
12/02/2025
StudyPlanned
Effectiveness of ABRYSVO® maternal respiratory syncytial virus (RSV) vaccine against RSV in infants in Western Pennsylvania (CASSATT)
United States
EU PAS number:
EUPAS1000000389
First published:
17/02/2025
StudyPlanned
Asymptomatic hyperuricemia: to treat or not to treat. A target trial emulation to assess major cardiorenal outcomes (HYPER-TTE-HARV)
Spain
United States
EU PAS number:
EUPAS1000000386
First published:
21/11/2024
StudyOngoing
Effectiveness of Pfizer-BioNTech COVID-19 mRNA vaccine against severe illness in the elderly in Finland (RWE_COVID19_2023)
Finland
EU PAS number:
EUPAS1000000376
First published:
29/04/2025
StudyOngoing
Comparative effectiveness and safety of omalizumab and dupilumab in children with asthma
Korea, Republic of
EU PAS number:
EUPAS1000000361
First published:
03/04/2025
StudyOngoing
VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe
Spain
EU PAS number:
EUPAS1000000337
First published:
02/07/2025
StudyPlanned
A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation
United States
EU PAS number:
EUPAS1000000327
First published:
14/02/2025
StudyPlanned